October 28, 2022 4:37pm

SLDB closed down -$0.70 to $6.11 after yesterday's trading at $0.44

on Thursday implementing reverse split with 231,543 shares traded

Beginning with the opening of trading on 11/28/22, the common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis under the existing symbol “SLDB” and a new CUSIP number 83422E 204.


At the effective time of the Reverse Stock Split, every fifteen (15) shares of the company’s issued and outstanding common stock will be automatically converted into one (1) issued and outstanding share of common stock without any change in the par value of $0.001 per share.

This will reduce the company’s number of shares of outstanding common stock from approximately 113.0 million shares to approximately 7.5 million shares.

Proportional adjustments will be made to the number of shares of common stock issuable upon exercise of the company’s outstanding stock options, restricted stock units, and warrants, as well as the applicable exercise price.


The Bottom line: let’s not forget as I had written, “Sharpen your pencil – new investment and management coming from Bain funds with an acquisition of AvantiBio and a $75 million private placement. Combined company is expected to have approximately $215 million in cash and investments, which is expected to fund the combined company into 2025 and support attainment of key milestones for lead gene therapy programs

Outstanding shares: 113 million

Float: 105.2 million shares